Medcan receives it’s Facility Inspection Letter from the Office of Drug Control (ODC)

The ODC notes “the inspectors found that the rooms inspected provided adequate security measures for cannabis plants and cannabis and cannabis resin”.

This article is from Project Herba for Health Care, Medical & Biotech

Medcan Australia (Medcan) is pleased to announce the receipt of it’s Facility Inspection Letter from the Office of Drug Control (ODC). 

This Facility Inspection Letter is a summary of the inspection performed by the ODC on the 29th October 2019 and summarizes the outcome of the Medcan facility inspection. The ODC notes “the inspectors found that the rooms inspected provided adequate security measures for cannabis plants and cannabis and cannabis resin”. 

Successful issue of this inspection letter is a significant milestone as it is the ODC’s formal advice that the design, construction, security measures, SOP’s and Risk Assessment implemented as part of Medcan’s Cannabis Research Area has been assessed and approved by the ODC. 

Comments from Craig Cochran – Managing Director, Founder, Medcan Australia: 

Medcan Australia Founder, Craig Cochran said: “This is a great achievement for all parties involved as it validates the design, construction and security protocols of our Cannabis Research area within the Medcan facility”. Craig Continued: “This successful approval by the ODC is the culmination of many, many months of hard work and dedication by our entire team. It is testament to the extremely high standard we have set for the design and construction of our facility”. 

Related Attachments

January 9th, 2020

9th-january-2020---medcan-australia---medcan-receives-it-s-facility-inspection-letter-from-the-office-of-drug-control-(odc).pdf ( 193.69 KB )